Vertex EVP Joy Liu sells 1,104 company shares

Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 1,104 shares of Vertex common stock in an open-market transaction at $425.02 per share.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 1,104 shares of Vertex common stock in an open-market transaction at $425.02 per share. The sale was made pursuant to a company-approved trading plan under Rule 10b5-1. After this transaction, Liu directly holds 20,729 shares of Vertex common stock.

Insider Trade Summary 10b5-1

Net Seller: 1,104 shares

Net Sell 1 txn

Insider Liu Joy

Role EVP and Chief Legal Officer

Sold 1,104 shs ($469K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,104	$425.02	$469K

Holdings After Transaction: Common Stock — 20,729 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Key Figures

Shares sold: 1,104 shares Sale price per share: $425.02 per share Shares owned after sale: 20,729 shares +1 more

4 metrics

Shares sold 1,104 shares Open-market sale of common stock on 2026-05-01

Sale price per share $425.02 per share Price for the 1,104 Vertex common shares sold

Shares owned after sale 20,729 shares Direct holdings following the reported transaction

Transactions classified as sales 1 transaction Form 4 transaction summary shows one sell transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, beneficially owned

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

beneficially owned financial

"total_shares_following_transaction": "20729.0000""

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vertex (VRTX) executive Joy Liu report in this Form 4?

Joy Liu reported selling 1,104 shares of Vertex common stock at $425.02 per share. The transaction was an open-market sale, and after it she directly holds 20,729 Vertex shares, according to the Form 4 filing.

Was Joy Liu’s VRTX stock sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes the sale was made under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on 11/25/2025, indicating the transaction was pre-scheduled rather than opportunistic.

How many Vertex (VRTX) shares did Joy Liu sell and at what price?

She sold 1,104 shares of Vertex common stock at a price of $425.02 per share. This was recorded as an open-market sale transaction and is classified as a non-derivative disposition in the Form 4 filing.

How many Vertex (VRTX) shares does Joy Liu own after this transaction?

Following the reported sale, Joy Liu directly holds 20,729 shares of Vertex common stock. This post-transaction balance is disclosed in the Form 4 as the total number of shares beneficially owned after the sale.

What role does Joy Liu hold at Vertex Pharmaceuticals (VRTX)?

Joy Liu serves as Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals. Her position is identified in the Form 4, which reports insider transactions for officers, directors, and certain large shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 05:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Joy

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		1,104	D	$425.02	20,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)